trending Market Intelligence /marketintelligence/en/news-insights/trending/j2KCzY3Iw5Wesq3aJDJO2w2 content esgSubNav
In This List

US FDA accepts Samsung Bioepis' application for Herceptin biosimilar

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


US FDA accepts Samsung Bioepis' application for Herceptin biosimilar

The U.S. Food and Drug Administration accepted Samsung Bioepis Co. Ltd.'s biologics license application for its biosimilar version of Roche Holding AG's breast cancer drug Herceptin.

If approved, SB3 will be commercialized in the U.S. by Merck & Co. Inc.

SB3 is Samsung Bioepis' first oncology biosimilar candidate submitted for regulatory approval in the U.S.